Bruker Corporation (NASDAQ:BRKR) Q3 2023 Earnings Call Transcript
Justin Ward: Thank you and good morning. I would like to welcome everyone to Bruker Corporation’s third quarter 2023 earnings conference call.
Stay updated with breaking news from Project Accelerate. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Justin Ward: Thank you and good morning. I would like to welcome everyone to Bruker Corporation’s third quarter 2023 earnings conference call.
Today Allergan Aesthetics, an AbbVie company, announces its fifth year of partnership with Girls Inc., this year supporting Project Accelerate, a program addressing inequality in the workplace that aims to accelerate young women's trajectories through college and career entry. The Allergan Aesthetics effort will ...
Through the partnership, women involved in Project Accelerate will have access to internship and early-career opportunities at AbbVie and Allergan Aesthetics.
Through its College Bound program, the nonprofit helps dozens of teenage girls navigate this stressful period and helps them pay for it. The deadline to apply for this year's program is Wednesday, Sept. 13.
Bruker Corp. signed a definitive agreement to acquire functional cell biology company Phenomex for $108 million as part of its Project Accelerate 2.0 strategy, which increases focus on the company’s emerging proteomics and spatial biology business. Bruker offered $1 per share, a 150% premium over the 40 cents per share closing price of Phenomex stock on Aug. 16. The all-cash transaction is slated to close in the fourth quarter of 2023.